Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

251.95
-1.3400-0.53%
Post-market: 251.950.00000.00%16:10 EDT
Volume:329.92K
Turnover:82.86M
Market Cap:16.68B
PE:19.28
High:256.35
Open:256.35
Low:247.03
Close:253.29
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:0.66
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):13.07
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:9.95
PE(LYR):-57.03

Loading ...

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

GlobeNewswire
·
Jun 12

Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer

TIPRANKS
·
Jun 09

Ascendis presents final Phase 3 PaTHway results for palopegteriparatide in adult hypoparathyroidism at ENDO 2026

Reuters
·
Jun 09

Ascendis Pharma to present rare endocrine disease data at Endocrine Society ENDO meeting

Reuters
·
Jun 09

Ascendis Pharma CFO Scott Thomas Smith acquires 100 common shares valued at $21,900

Reuters
·
Jun 03

Ascendis Pharma director Jean Jacques Bienaime acquires USD 111,986 in common shares

Reuters
·
Jun 02

Ascendis Pharma CFO Scott Thomas Smith acquires $55,830 of ordinary shares

Reuters
·
Jun 02

Ascendis Pharma director Jean Jacques Bienaime reports purchase of ordinary shares worth $95,120.5

Reuters
·
May 28

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading

MT Newswires Live
·
May 26

J.P. Morgan Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
May 20

Ascendis Pharma Initiated at Buy by Citigroup

Dow Jones
·
May 19

Assessing Ascendis Pharma (ASND) Valuation After Recent Soft Trading And Perceived Discount

Simply Wall St.
·
May 19

Ascendis Pharma initiated with a Buy at Citi

TIPRANKS
·
May 19

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading

MT Newswires Live
·
May 18

Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
May 18

Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
May 16

Ascendis Pharma price target raised to $329 from $324 at Evercore ISI

TIPRANKS
·
May 15

Ascendis EVP Flemming Jensen sells 19,460 shares for $4.64 million

Reuters
·
May 13

Ascendis Pharma Is Maintained at Overweight by Barclays

Dow Jones
·
May 11

Ascendis Pharma price target raised to $345 from $342 at Barclays

TIPRANKS
·
May 11